BDNF and amyotrophic lateral sclerosis: However, clinical trials with recombinant BDNF in patients with ALS have yielded disappointing results that have been attributed to the poor pharmacokinetics and pharmacodynamics of delivered exogenous BDNF (Colucci-D'Amato et al., 2020).